美国一家法院以心脏阀门装置市场竞争减少为由,阻止Edwards945M美元购买JenaValve, A U.S. court blocked Edwards' $945M purchase of JenaValve over antitrust concerns, citing reduced competition in heart valve device markets.

美国地区法院以公平贸易委员会的反托拉斯关切为由,阻止Edwards Lifesciences公司9.45亿美元收购JenaValve。 A U.S. District Court has blocked Edwards Lifesciences' $945 million acquisition of JenaValve, citing antitrust concerns from the FTC. 公平贸易委员会称,合并会减少美国市场对转胃动脉更换装置的竞争,可能限制病人获得创新治疗。 The FTC argued the merger would reduce competition in the U.S. market for transcatheter aortic valve replacement devices, potentially limiting patient access to innovative treatments. 爱德华兹不同意这一裁决, 维持协议将有利于有大动脉吐的患者. Edwards disagreed with the ruling, maintaining the deal would have benefited patients with aortic regurgitation. 这一决定标志着Edwards增长战略的挫折,凸显出对医疗装置合并的监管监督力度加大。 The decision marks a setback for Edwards’ growth strategy and highlights increased regulatory scrutiny of medical device mergers.